Tempus AI

Piper Sandler upgraded Tempus AI from "Neutral" to "Overweight" and raised the price target from $56 to $76, after which the stock rose about 2.1% in premarket trading. The analyst cites three growth drivers: the planned acquisition of Personalis with a tumor‑informed MRD platform, the positive readout of the INTerpath‑001 study, and FDA approval of the tumor test xT CDx, which enables a uniform ADLT pricing. The test xF is also mentioned as a potential follow‑on product launch in the second half of 2027. » Más en de.investing.com

Tempus AI shares rose 2.7% in premarket trading after positive analyst comments accompanying the S-4 filing for the Personalis acquisition. Piper Sandler upgraded to "Overweight" and raised its price target from $56 to $76, while Canaccord reiterated a buy rating with an $80 target. The S-4 discloses a competitive sale process and underscores the strategic value of the deal. Tempus showed a move into profitability in the second quarter and raised its 2026 revenue forecast to about $1.6 billion. » Más en de.investing.com

ARK Invest sold 59,276 shares of Tempus AI worth $4,059,220 and also reduced holdings in Twist Bioscience. At the same time, ARK bought 47,793 shares of Veracyte for $2,116,751 and, via ARKG, acquired 5,085 shares of Scribe Therapeutics for $161,194. Smaller sales involved Roblox and Brera Holdings. The reallocations point to a stronger portfolio focus on biotech and a reduction of selected technology names. » Más en de.investing.com